Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 10/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4527136 | 0.99 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| SCHEMBL4522191 | 0.90 | ADRA1A (0.54) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| SCHEMBL4528834 | 0.90 | ADRA1A (0.54) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL4527648 | 0.89 | ADRA1D (0.53) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| SCHEMBL5807739 | 0.88 | ADRA1A (0.52) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| SCHEMBL4528199 | 0.87 | HTR1A (0.50) | HTR1ADRD2HTR7RAB9A | |
| Hydrochloric Acid SCHEMBL4526590 | 0.86 | HTR1A (0.49) | HTR1ADRD2HTR7RAB9A | |
| SCHEMBL4527930 | 0.85 | ADRA1D (0.49) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL4524947 | 0.84 | ADRA1D (0.49) | ADRA1AADRA1DADRA1BHTR1ADRD2 | |
| SCHEMBL4526930 | 0.84 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BHTR1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | ADRA1A 3/4885ADRA1D 1/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.